References
- Azziz, R. (2016). PCOS in 2015: New insights into the genetics of polycystic ovary syndrome. Nature Reviews. Endocrinology, 12(2), 74–75. https://doi.org/https://doi.org/10.1038/nrendo.2015.230
- Bas, D. C., Rogers, D. M., & Jensen, J. H. (2008). Very fast prediction and rationalization of pKa values for protein-ligand complexes. Proteins, 73(3), 765–783. https://doi.org/https://doi.org/10.1002/prot.22102
- Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The protein data bank. Nucleic Acids Research, 28(1), 235–242. https://doi.org/https://doi.org/10.1093/nar/28.1.235
- Buntru, A., Trepte, P., Klockmeier, K., Schnoegl, S., & Wanker, E. E. (2016). Current approaches toward quantitative mapping of the interactome. Frontiers in Genetics, 7(74), 74. https://doi.org/https://doi.org/10.3389/fgene.2016.00074
- Cesa, L. C., Mapp, A. K., & Gestwicki, J. E. (2015). Direct and propagated effects of small molecules on protein-protein interaction networks. Frontiers in Bioengineering and Biotechnology, 3(119), 119. https://doi.org/https://doi.org/10.3389/fbioe.2015.00119
- Chen, X., Liu, P., Wang, Q., Li, Y., Fu, L., Fu, H., Zhu, J., Chen, Z., Zhu, W., Xie, C., & Lou, L. (2018). DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction. Cancer Letters, 434, 70–80. https://doi.org/https://doi.org/10.1016/j.canlet.2018.07.012
- Chène, P. (2006). Drugs targeting protein-protein interactions. ChemMedChem, 1(4), 400–411. https://doi.org/https://doi.org/10.1002/cmdc.200600004
- Cierpicki, T., & Grembecka, J. (2015). Targeting protein-protein interactions in hematologic malignancies: Still a challenge or a great opportunity for future therapies? Immunological Reviews, 263(1), 279–301. https://doi.org/https://doi.org/10.1111/imr.12244
- Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/https://doi.org/10.1038/srep42717
- Darnell, S. J., LeGault, L., & Mitchell, J. C. (2008). KFC server: Interactive forecasting of protein interaction hot spots. Nucleic Acids Research, 36(Web Server issue), W265–W269. https://doi.org/https://doi.org/10.1093/nar/gkn346
- Desmond Molecular Dynamics System, Schrödinger. (2018). D. E. Shaw Research, Maestro-Desmond Interoperability Tools.
- Dutta Gupta, S., Bommaka, M. K., & Banerjee, A. (2019). Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer. European Journal of Medicinal Chemistry, 178, 48–63. https://doi.org/https://doi.org/10.1016/j.ejmech.2019.05.073
- Egan, W. J., Merz, K. M., Jr., & Baldwin, J. J. (2000). Prediction of drug absorption using multivariate statistics. Journal of Medicinal Chemistry, 43(21), 3867–3877. https://doi.org/https://doi.org/10.1021/jm000292e
- Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., & Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47(7), 1739–1749. https://doi.org/https://doi.org/10.1021/jm0306430
- Gerrard, J. A., Hutton, C. A., & Perugini, M. A. (2007). Inhibiting protein-protein interactions as an emerging paradigm for drug discovery. Mini Reviews in Medicinal Chemistry, 7(2), 151–157. https://doi.org/https://doi.org/10.2174/138955707779802561
- Ghose, A. K., Viswanadhan, V. N., & Wendoloski, J. J. (1999). A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. Journal of Combinatorial Chemistry, 1(1), 55–68. https://doi.org/https://doi.org/10.1021/cc9800071
- Grosdidier, S., & Fernández-Recio, J. (2008). Identification of hot-spot residues in protein-protein interactions by computational docking. BMC Bioinformatics, 9(1), 447. https://doi.org/https://doi.org/10.1186/1471-2105-9-447
- Grover, A., Shandilya, A., Agrawal, V., Pratik, P., Bhasme, D., Bisaria, V. S., & Sundar, D. (2011). Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A. BMC Bioinformatics, 12(Suppl 1), S30. https://doi.org/https://doi.org/10.1186/1471-2105-12-S1-S30
- Gu, M., Yu, Y., Gunaherath, G. M., Gunatilaka, A. A., Li, D., & Sun, D. (2014). Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells. Investigational New Drugs, 32(1), 68–74. https://doi.org/https://doi.org/10.1007/s10637-013-9987-y
- Harder, E., Damm, W., Maple, J., Wu, C., Reboul, M., Xiang, J. Y., Wang, L., Lupyan, D., Dahlgren, M. K., Knight, J. L., Kaus, J. W., Cerutti, D. S., Krilov, G., Jorgensen, W. L., Abel, R., & Friesner, R. A. (2016). OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. Journal of Chemical Theory and Computation, 12(1), 281–296. https://doi.org/https://doi.org/10.1021/acs.jctc.5b00864
- Huang, W., Ye, M., Zhang, L. R., Wu, Q. D., Zhang, M., Xu, J. H., & Zheng, W. (2014). FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation. Molecular Cancer, 13, 150. https://doi.org/https://doi.org/10.1186/1476-4598-13-150
- Ivanov, A. A., Khuri, F. R., & Fu, H. (2013). Targeting protein-protein interactions as an anticancer strategy. Trends in Pharmacological Sciences, 34(7), 393–400. https://doi.org/https://doi.org/10.1016/j.tips.2013.04.007
- Jacobsen, A. V., & Silke, J. (2016). The importance of being chaperoned: HSP90 and necroptosis. Cell Chemical Biology, 23(2), 205–207. https://doi.org/https://doi.org/10.1016/j.chembiol.2016.02.003
- Keskin, O., Tuncbag, N., & Gursoy, A. (2016). Predicting protein-protein interactions from the molecular to the proteome level. Chemical Reviews, 116(8), 4884–4909. https://doi.org/https://doi.org/10.1021/acs.chemrev.5b00683
- Kokosar, M., Benrick, A., Perfilyev, A., Fornes, R., Nilsson, E., Maliqueo, M., Behre, C. J., Sazonova, A., Ohlsson, C., Ling, C., & Stener-Victorin, E. (2016). Epigenetic and transcriptional alterations in human adipose tissue of polycystic ovary syndrome. Scientific Reports, 6(1), 22883. https://doi.org/https://doi.org/10.1038/srep22883
- Laskowski, R. A., & Swindells, M. B. (2011). LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. Journal of Chemical Information and Modeling, 51(10), 2778–2786. https://doi.org/https://doi.org/10.1021/ci200227u
- Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., Tang, A., Gabriel, G., Ly, C., Adamjee, S., Dame, Z. T., Han, B., Zhou, Y., & Wishart, D. S. (2014). DrugBank 4.0: Shedding new light on drug metabolism. Nucleic Acids Research, 42(Database issue), D1091–1097. https://doi.org/https://doi.org/10.1093/nar/gkt1068
- Li, D., Li, C., Li, L., Chen, S., Wang, L., Li, Q., Wang, X., Lei, X., & Shen, Z. (2016). Natural product kongensin A is a non-canonical HSP90 inhibitor that blocks RIP3-dependent necroptosis. Cell Chemical Biology, 23(2), 257–266. https://doi.org/https://doi.org/10.1016/j.chembiol.2015.08.018
- Li, T., Chen, X., Chen, X., Ma, D. L., Leung, C. H., & Lu, J. J. (2016). Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. Scientific Reports, 6, 37997. https://doi.org/https://doi.org/10.1038/srep37997
- Li, T., Chen, X., Dai, X.-Y., Wei, B., Weng, Q.-J., Chen, X., Ouyang, D.-F., Yan, R., Huang, Z.-J., Jiang, H.-L., Zhu, H., & Lu, J.-J. (2017). Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor. Toxicology and Applied Pharmacology, 330, 65–73. https://doi.org/https://doi.org/10.1016/j.taap.2017.07.006
- Li, Y., Karagöz, G. E., Seo, Y. H., Zhang, T., Jiang, Y., Yu, Y., Duarte, A. M. S., Schwartz, S. J., Boelens, R., Carroll, K., Rüdiger, S. G. D., & Sun, D. (2012). Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90. The Journal of Nutritional Biochemistry, 23(12), 1617–1626. https://doi.org/https://doi.org/10.1016/j.jnutbio.2011.11.004
- Li, Y., Zhang, T., Schwartz, S. J., & Sun, D. (2009). New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 12(1-2), 17–27. https://doi.org/https://doi.org/10.1016/j.drup.2008.12.002
- Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1-3), 3–26. https://doi.org/https://doi.org/10.1016/s0169-409x(00)00129-0
- Liu, S., Liu, C., & Deng, L. (2018). Machine learning approaches for protein–protein interaction hot spot prediction: Progress and comparative assessment. Molecules, 23(10), 2535. https://doi.org/https://doi.org/10.3390/molecules23102535
- Mabonga, L., & Kappo, A. P. (2019). Protein-protein interaction modulators: Advances, successes and remaining challenges. Biophysical Reviews, 11(4), 559–581. https://doi.org/https://doi.org/10.1007/s12551-019-00570-x
- Macalino, S. J. Y., Basith, S., Clavio, N. A. B., Chang, H., Kang, S., & Choi, S. (2018). Evolution of in silico strategies for protein-protein interaction drug discovery. Molecules, 23(8), 1963. https://doi.org/https://doi.org/10.3390/molecules23081963
- Mak, O. W., Chand, R., Reynisson, J., & Leung, I. K. H. (2019). Identification of isoform-selective ligands for the middle domain of heat shock protein 90 (Hsp90). International Journal of Molecular Sciences, 20(21), 5333. https://doi.org/https://doi.org/10.3390/ijms20215333
- Muegge, I., Heald, S. L., & Brittelli, D. (2001). Simple selection criteria for drug-like chemical matter. Journal of Medicinal Chemistry, 44(12), 1841–1846. https://doi.org/https://doi.org/10.1021/jm015507e
- Ofran, Y., & Rost, B. (2007). Protein-protein interaction hotspots carved into sequences. PLoS Computational Biology, 3(7), e119. https://doi.org/https://doi.org/10.1371/journal.pcbi.0030119
- Parida, P., Bhowmick, S., Saha, A., & Islam, M. A. (2020). Insight into the screening of potential beta-lactamase inhibitors as anti-bacterial chemical agents through pharmacoinformatics study. Journal of Biomolecular Structure and Dynamics, 1–20. https://doi.org/https://doi.org/10.1080/07391102.2020.1720819
- Qiao, Y., Xiong, Y., Gao, H., Zhu, X., & Chen, P. (2018). Protein-protein interface hot spots prediction based on a hybrid feature selection strategy. BMC Bioinformatics, 19(1), 14. https://doi.org/https://doi.org/10.1186/s12859-018-2009-5
- Roe, S. M., Ali, M. M. U., Meyer, P., Vaughan, C. K., Panaretou, B., Piper, P. W., Prodromou, C., & Pearl, L. H. (2004). The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell, 116(1), 87–98. https://doi.org/https://doi.org/10.1016/S0092-8674(03)01027-4
- Rosell, M., & Fernández-Recio, J. (2018). Hot-spot analysis for drug discovery targeting protein-protein interactions. Expert Opinion on Drug Discovery, 13(4), 327–338. https://doi.org/https://doi.org/10.1080/17460441.2018.1430763
- Salentin, S., Schreiber, S., Haupt, V. J., Adasme, M. F., & Schroeder, M. (2015). PLIP: Fully automated protein-ligand interaction profiler. Nucleic Acids Research, 43(W1), W443–447. https://doi.org/https://doi.org/10.1093/nar/gkv315
- Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016). Small molecules, big targets: Drug discovery faces the protein-protein interaction challenge. Nature Reviews. Drug Discovery, 15(8), 533–550. https://doi.org/https://doi.org/10.1038/nrd.2016.29
- Shelley, J. C., Cholleti, A., Frye, L. L., Greenwood, J. R., Timlin, M. R., & Uchimaya, M. (2007). Epik: A software program for pK(a) prediction and protonation state generation for drug-like molecules. Journal of Computer-Aided Molecular Design, 21(12), 681–691. https://doi.org/https://doi.org/10.1007/s10822-007-9133-z
- Shin, W. H., Christoffer, C. W., & Kihara, D. (2017). In silico structure-based approaches to discover protein-protein interaction-targeting drugs. Methods (San Diego, Calif.), 131, 22–32. https://doi.org/https://doi.org/10.1016/j.ymeth.2017.08.006
- Sreeramulu, S., Jonker, H. R., Langer, T., Richter, C., Lancaster, C. R., & Schwalbe, H. (2009). The human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopy. The Journal of Biological Chemistry, 284(6), 3885–3896. https://doi.org/https://doi.org/10.1074/jbc.M806715200
- Tang, R., Ding, X., & Zhu, J. (2019). Kisspeptin and Polycystic Ovary Syndrome. Frontiers in Endocrinology, 10(298), 298. https://doi.org/https://doi.org/10.3389/fendo.2019.00298
- Tuncbag, N., Keskin, O., & Gursoy, A. (2010). HotPoint: Hot spot prediction server for protein interfaces. Nucleic Acids Research, 38(Web Server issue), W402–406. https://doi.org/https://doi.org/10.1093/nar/gkq323
- Veber, D. F., Johnson, S. R., Cheng, H. Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615–2623. https://doi.org/https://doi.org/10.1021/jm020017n
- Wang, L., Zhang, L., Li, L., Jiang, J., Zheng, Z., Shang, J., Wang, C., Chen, W., Bao, Q., Xu, X., Jiang, Z., Zhang, J., & You, Q. (2019). Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer. Science Advances, 5(9), eaax2277. https://doi.org/https://doi.org/10.1126/sciadv.aax2277
- Yu, Y., Hamza, A., Zhang, T., Gu, M., Zou, P., Newman, B., Li, Y., Gunatilaka, A. A. L., Zhan, C.-G., & Sun, D. (2010). Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochemical Pharmacology, 79(4), 542–551. https://doi.org/https://doi.org/10.1016/j.bcp.2009.09.017
- Zhang, T., Hamza, A., Cao, X., Wang, B., Yu, S., Zhan, C.-G., & Sun, D. (2008). A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Molecular Cancer Therapeutics, 7(1), 162–170. https://doi.org/https://doi.org/10.1158/1535-7163.MCT-07-0484
- Zhang, T., Li, Y., Yu, Y., Zou, P., Jiang, Y., & Sun, D. (2009). Characterization of celastrol to inhibit hsp90 and cdc37 interaction. The Journal of Biological Chemistry, 284(51), 35381–35389. https://doi.org/https://doi.org/10.1074/jbc.M109.051532
- Zinzalla, G., & Thurston, D. E. (2009). Targeting protein-protein interactions for therapeutic intervention: A challenge for the future. Future Medicinal Chemistry, 1(1), 65–93. https://doi.org/https://doi.org/10.4155/fmc.09.12